• Explore /
  • Poster
  • / IL believe: A phase 1/2, open-label, dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab or standard-of-care chemotherapy in patients with locally advanced or metastatic solid tumors.

IL believe: A phase 1/2, open-label, dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab or standard-of-care chemotherapy in patients with locally advanced or metastatic solid tumors.

Abstract Poster

Authors

null

Alexander Starodub

The Christ Hospital, Cincinnati, OH

Alexander Starodub , Nashat Y. Gabrail , Ying Zhang , Davis Y Torrejon Castro , Sibel Slavsky , Stina Mui Singel , John D. Powderly

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

NCT05081609

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS2695)

DOI

10.1200/JCO.2022.40.16_suppl.TPS2695

Abstract #

TPS2695

Poster Bd #

335a

Abstract Disclosures

Similar Posters

First Author: Mariam Jamal-Hanjani

First Author: Robert A. Ramirez

First Author: Jason Alan Chesney

First Author: Jonathan Alexander Chatzkel